Dominic Borie
Directeur Technique/Scientifique/R&D chez KYVERNA THERAPEUTICS, INC.
Fortune : 6 M $ au 31/05/2024
Postes actifs de Dominic Borie
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| KYVERNA THERAPEUTICS, INC. | Directeur Technique/Scientifique/R&D | 13/10/2022 | - |
| Directeur/Membre du Conseil | 01/01/2020 | 13/10/2022 | |
| Directeur Général | 01/01/2020 | 13/10/2022 | |
| President | 01/01/2020 | 13/10/2022 |
Historique de carrière de Dominic Borie
Anciens postes connus de Dominic Borie
| Sociétés | Poste | Début | Fin |
|---|---|---|---|
| Stanford University | Corporate Officer/Principal | - | - |
| AMGEN INC. | Directeur Technique/Scientifique/R&D | - | - |
| HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY | Corporate Officer/Principal | - | - |
Genentech, Inc.
 Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - | - |
| ALLOGENE THERAPEUTICS, INC. | Directeur/Membre du Conseil | - | - |
Formation de Dominic Borie
| The University of Texas at Austin | Doctorate Degree |
| North Carolina State University | Undergraduate Degree |
Statistiques
Internationale
| Etats-Unis | 8 |
| Irlande | 2 |
Opérationnelle
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Chief Tech/Sci/R&D Officer | 2 |
Sectorielle
| Health Technology | 6 |
| Consumer Services | 4 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| KYVERNA THERAPEUTICS, INC. | Health Technology |
| ALLOGENE THERAPEUTICS, INC. | Health Technology |
| AMGEN INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Horizon Therapeutics Plc
 Horizon Therapeutics Plc Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland. | Health Technology |
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Bourse
- Insiders
- Dominic Borie
- Expérience
